ZAI LAB LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
ZAI LAB LIMITED (ZLAB) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $27.93 per share as of 2017-09-30, per its 20-F filed 2020-04-29.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2020-04-29
- 2017-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $27.93.
- 2017-05-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $9.60.
- 2016-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $8.04.
- 2016-08-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $8.04.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2017-09-30 | $27.93 20-F · filed 2020-04-29 |
| 2017-05-31 | $9.60 20-F · filed 2020-04-29 |
| 2016-12-31 | $8.04 20-F · filed 2019-03-29 |
| 2016-08-31 | $8.04 20-F · filed 2019-03-29 |
| 2016-03-31 | $7.14 20-F · filed 2019-03-29 |
| 2015-10-31 | $1.92 20-F · filed 2018-04-30 |
| 2015-03-31 | $1.62 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |